US4933165A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Coenzyme Q10 with HMG-CoA reductase inhibitors
Assignee: Merck and Co Inc
•
Filing: 1989-01-18
•
Granted: 1990-06-12
•
Expires: 2009-01-18
Abstract
Abstract A pharmaceutical composition and method of counteracting HMG-CoA reductase inhibitor-associated myopathy is disclosed. The method comprises the adjunct administration of an effective amount of a HMG-CoA reductase inhibitor and an effective amount of Coenzyme Q 10 .
Inventors
- 👤 Michael S. Brown
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 08:14
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
33 words
A pharmaceutical composition comprising a pharmaceutical carrier and an effective antihypercholesterolemic amount of an HMG-CoA reductase inhibitor and an amount of Coenzyme Q 10 effective to counteract HMG-CoA reductase inhibitor-associated skeletal muscle myopathy.
Claim 2
Dependent Claim
33 words
A pharmaceutical composition comprising a pharmaceutical carrier and an effective antihypercholesterolemic amount of an HMG-CoA reductase inhibitor and an amount of Coenzyme Q 10 effective to counteract HMG-CoA reductase inhibitor-associated skeletal muscle myopathy.
Claim 3
Dependent Claim
19 words
A composition of claim 1 in which the HMG-CoA reductase inhibitor is selected from: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]-hept-6-enoate.
Claim 4
Independent Claim
45 words
A method of counteracting HMG-CoA reductase inhibitor-associated skeletal muscle myopathy in a subject in need of such treatment which comprises the adjunct administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor and an effective amount of Coenzyme Q 10 to counteract said myopathy.
Claim 5
Independent Claim
45 words
A method of counteracting HMG-CoA reductase inhibitor-associated skeletal muscle myopathy in a subject in need of such treatment which comprises the adjunct administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor and an effective amount of Coenzyme Q 10 to counteract said myopathy.
Claim 6
Dependent Claim
23 words
A method of claim 3 in which the HMG-CoA reductase inhibitor is selected from the group consisting of: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]-hept-6-enoate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-11 | 1993-12-11 | 1994-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-11 | 1997-12-11 | 1998-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-11 | 2001-12-11 | 2002-06-12 | $7700.00 | Window Closed / Lapsed |